ON
Oncolytics Biotech Inc.
ONCY · NASDAQ
$0.78 -6.05% (-$0.05)
1M -5.19%
Market Cap $81.6M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.4
48.7% downside
Current Price
$0.78
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ONCY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 1,485.13%
ROA 498.10%
Asset turnover 0.00x
Debt
63 /100
Moderate Current ratio 1.35x
Debt/Equity N/A
Int. coverage N/A
Stability
69 /100
Stable Beta 1.15x
EPS volatility 3.94%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ONCY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jared Kelly
Employees
29
Headquarters
San Diego
Upcoming events
11 NOV
Earnings
Upcoming earnings report